Fibrates are widely used to treat hypertriglyceridemia, a risk factor for arteriosclerosis, but these compounds have been associated with renal dysfunction. This study aimed to investigate the effects of fibrates on renal function in relatively healthy adult subjects with no cardiovascular diseases. Methods: This retrospective study included 558 outpatients who were prescribed 160 mg fenofibrate (fenofibrate group) or 10 mg atorvastatin (control group) between August 2007 and October 2015. The groups were randomly matched using propensity scores at a 1:1 ratio. Serum creatinine levels and estimated glomerular filtration rates before and after treatment were compared between the two groups. Results: Patients in the fenofibrate group showed greater changes in serum creatinine levels than those in the control group (9.73%±9.83% versus -0.89%±7.37%, P<0.001). Furthermore, 55.1% of patients in the fenofibrate group, but only 6.1% of those in the control group, exhibited a serum creatinine level increase ≥0.1 mg/dL (P<0.001). The fenofibrate group showed significantly greater declines in the estimated glomerular filtration rate than the control group (-10.1%±9.48% versus 1.42%±9.42%, P<0.001). Moreover, 34.7% of the fenofibrate group, but only 4.1% of the control group, exhibited an estimated glomerular filtration rate decrease ≥10 mL/min·1.73 m 2 (P<0.001). Conclusion: Fenofibrate treatment resulted in increased serum creatinine levels and reduced estimated glomerular filtration rates in a primary care setting. Therefore, regular renal function monitoring should be considered essential during fibrate administration.
introduCtion
Metabolic syndrome, diabetes, and obesity are highly correlated with hypertriglyceridemia, high low-density lipoprotein (LDL) cholesterol, and low high-density lipoprotein (HDL) cholesterol. 1) Conventionally, statins have been widely used to treat hyperlipidemia; these 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors have a significant role in reducing the risk of cardiovascular diseases and stroke.
2) It has recently emerged that high serum triglyceride (TG) levels are a significant risk factor for arteriosclerosis.
3)
The American College of Cardiology/American Heart Association Guidelines, published in 2013, 4) did not include recommendations for the treatment of elevated TG levels. The first goal of the previously published Adult Treatment Panel III 5) was to reduce LDL cholesterol levels to a target level, when TG levels were between 200 mg/dL and 499 mg/dL. The second goal was to reduce non-HDL cholesterol to a target level. Drug treatments are recommended for TG levels ≥500 mg/ dL, in order to reduce TG levels and prevent acute pancreatitis. Among the drugs used to reduce TG levels, fibrates have been more widely used than nicotinic acid because of their relative efficacy and lower risk of adverse reactions. 6) Fibrates are peroxisome proliferator-activated receptor (PPAR)-α agonists that reduce serum TG levels and increase serum HDL cholesterol levels.
1,7)
Even though fibrates have been reported to show fewer adverse reactions than other agents, they increase the frequency of myopathy, gallstones, and phlebothrombosis. 3, 8) While they are not associated with an increased risk of renal failure, they may increase serum creatinine (Cr) levels. [9] [10] [11] [12] [13] However, most of the previous studies have been conducted in patients with chronic diseases such as diabetes, hypertension, and chronic renal failure. 14) A large-scale randomized controlled clinical trial of the efficacy of fenofibrate in coronary artery disease prevention was performed in patients with diabetes who were treated for 5 years. In this study, 2% of subjects showed elevated serum Cr levels >2.3 mg/dL, with mean levels that were 0.11-0.14 mg/dL higher than those of the control group (CG) during the study period. In addition, serum Cr levels declined in some patients after they stopped taking fenofibrate. 10) These findings indicated that fenofibrate increased serum Cr levels in patients with chronic diseases such as diabetes, hypertension, and chronic renal failure. We were interested in whether this compound affected renal function in relatively healthy adults without cardiovascular disease who are commonly seen in the primary care setting.
Thus, the present study aimed to investigate the relationship between fibrate treatment and changes in renal function in relatively healthy adults with no cardiovascular diseases.
Methods

study subjects
The present retrospective study identified 146 patients with hypertriglyceridemia who had visited the department of family medicine in Wonkwang University Sanbon Hospital in Gunpo-si between November 2007 and July 2015 and had been prescribed 160 mg fenofibrate.
The study was approved by the institutional review board (IRB) of Wonkwang University Sanbon Hospital (IRB no. 7302-201610).
Patients with coronary artery, peripheral vascular, or cerebrovascular diseases were excluded from the study. Eighty-three patients for whom serum Cr data prior to treatment and for 1-12 months after treatment initiation were available were selected as subjects. Subsequently the following patients were excluded: two patients with renal dysfunction and Cr levels >1.5 mg/dL prior to treatment; 10 patients with treatment duration <1 month; and nine patients whose medical records did not include height or body weight information. For eight patients, serum TG levels were reduced by <90 mg/dL after treatment; these patients were also excluded because they were regarded as untreated with fenofibrate. Thus, 54 patients were included in the experimental fenofibrate group (FG).
For the CG, patients with high LDL cholesterol who were prescribed atorvastatin, instead of fenofibrate, were selected. Atorvastatin is mainly metabolized in the liver by cytochrome P450 15) and has not been associated with kidney damage; instead, a protective effect on the kidney has been reported in diabetes. 16) A retrospective analysis of the same hospital department from August 2007 to October 2015
showed that 412 patients were prescribed 10 mg atorvastatin; of these, 298 patients for whom serum Cr data prior to treatment and for 1-12 months after treatment initiation were available were selected as study subjects. In this group, two patients who had renal dysfunction with Cr levels >1.5 mg/dL prior to treatment were excluded, as were 35 patients with treatment duration <1 month, and 14 patients whose medical records did not include height information. Finally, 246 patients were selected as the CG.
test Methods
Blood samples were collected from patients after an 8-hour fast, and total cholesterol levels were measured using an enzymatic colorimetric method on an automatic analyzer (ARCHITECT c8000 or ARCHI-TECT c16000; Abbott Laboratories, Abbott, IL, USA). TG levels were measured using the glycerol-blanking method; LDL-and HDL cholesterol levels were directly measured using the selective solubilization and modified enzymatic methods, respectively; and serum Cr levels were measured using the kinetic Jaffe reaction method. These analyses were performed using an automatic analyzer. The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Dis- 
outcomes
The present study compared changes in serum Cr levels and eGFR between FG patients and CG patients before and after administration of 160 mg fenofibrate or 10 mg atorvastatin, respectively, for 1-12 months. In each group, the primary outcome was defined as the percentage change in serum Cr levels and eGFR. The secondary outcome was defined as the proportion of patients with a serum Cr level increase ≥0.1 mg/dL and an eGFR reduction ≥10 mL/min·1.73 m 2 after treatment.
statistical Analysis
Statistical analyses were conducted using the IBM SPSS software ver.
22.0 (IBM Corp., Armonk, NY, USA). Continuous variables were expressed as mean values and were compared between two groups by independent t-tests; the before and after values were compared using paired t-tests. TG levels were log transformed because they were analyzed using a nonparametric test. TG levels were presented as the median and the interquartile range (25th and 75th percentiles). Categorical variables were expressed as percentages and were compared using the chi-square test; when the expected frequency of the cell was <5, the nonparametric Fisher's exact test was used.
To match FG and CG patients, a propensity score matching (PSM) Values are presented as mean±standard deviation or number (%), with the exception of triglyceride levels, which are presented as the median and the interquartile range. Continuous variables were analyzed using the t-test and categorical variables were analyzed using the chi-square test. *Never, non-drinker, and moderate alcohol intake ≤14 units and ≤7 units per week for male and female subjects, respectively; risk alcohol intake ≥15 units and ≥8 units per week for male and female subjects, respectively. † Calculated using the Chronic Kidney Disease Epidemiology Collaboration guidelines. Values are presented as mean±standard deviation or number (%), with the exception of triglyceride levels, which are presented as the median and the interquartile range. Continuous variables were analyzed using the t-test and categorical variables were analyzed using the chi-square test. Propensity score matching analysis was performed after adjusting for age, gender, baseline BMI, hypertension, DM, smoking status, alcohol intake, treatment duration, and baseline creatinine level. BMI, body mass index; DM, diabetes mellitus. *Never, non-drinker, and moderate alcohol intake ≤14 units and ≤7 units per week for male and female subjects, respectively; risk alcohol intake ≥15 units and ≥8 units per week for male and female subjects, respectively. † Calculated using the Chronic Kidney Disease Epidemiology Collaboration guidelines. Fenofibrate was approved by the US Food and Drug Administration in 1998 for the treatment of hypertriglyceridemia and atherogenic dyslipidemia. 19) It is a synthetic ligand that activates PPAR-α and has been shown to elevate HDL cholesterol by 10%-25% and reduce LDL cholesterol and TG levels by 5%-20% and 20%-50%, respectively.
19-21)
Although fenofibrate-related nephrotoxicity has not been well-recognized clinically, 22) this side effect was recently highlighted by a number of studies. 19, 23, 24) There are several hypotheses relating to the mechanisms underlying fenofibrate-associated nephrotoxicity. Fenofibrate may impair the generation of vasodilatory prostaglandins, leading to decreased dilation of the afferent arteriole; this compromises glomerular capillary pressure and reduces the perfusion of the kidneys. [25] [26] [27] Alternatively, fenofibrate may competitively inhibit Cr secretion in the proximal tubular lumen, [28] [29] [30] or increase endogenous Cr production.
31)
Broeders et al. 25 ) studied 27 patients (eight with renal failure and 19 who had undergone a kidney transplant) who showed nephrotoxicity after taking fibrates; this study defined nephrotoxicity as a serum Cr level increase ≥0.2 mg/dL. These results showed that the mean serum
Cr level increased by 40%, causing 24 patients to discontinue the treatment. The mean time taken to observe this serum Cr level elevation was 1.9 months, and the serum Cr levels reverted back to pre-treatment values in 18 of the 24 patients who discontinued fibrate medication. In the present study, a serum Cr increase ≥0.2 mg/dL over initial levels was observed in 16.3% of patients who took fenofibrate. Furthermore, Lipscombe et al. 28 ) studied 10 male patients with a past history of renal failure who showed a mean serum Cr increase of 35% after fibrate treatment, with a mean time of 78 days to elevation. These serum
Cr levels also decreased after drug withdrawal. In the present study, the mean serum Cr level increased by 9.73%±9.83% after fenofibrate treatment. These two studies indicate that fibrate treatment increased serum Cr levels in patients with nephropathy. 14) The results of the present study indicate that elevation of serum Cr levels was reported in subjects with normal renal function, but that the elevations were less marked than in previous studies. 25, 28) A retrospective study of 428 subjects conducted in 2012 32) reported that 115 patients (27%) showed a serum Cr level increase ≥0.3 mg/dL within 6 months of fenofibrate treatment initiation; multivariable regression analysis found that nephrotoxicity correlated with a past history of renal disease and high initial levels of fenofibrate. The present study was also a retrospective study, but it used PSM in order to address the limitations of this previous study. ; it reported a 0.93-1.10-mg/dL increase in Values are presented as mean±standard deviation or number (%). Continuous variables were analyzed using the t-test and categorical variables were analyzed using the chisquare test with the exception of eGFR decrease ≥20 mL/min·1.73 m 2 and eGFR decrease ≥20%. Cr, creatinine; eGFR, estimated glomerular filtration rate. *Calculated using Chronic Kidney Disease Epidemiology Collaboration guidelines. † Which were analyzed by Fisher's exact test.
serum Cr levels within 1 year of the initiation of fenofibrate administration. However, no statistical significance was reported. The AC-CORD Renal Ancillary Study 34) was a prospective follow-up study of the ACCORD study that was conducted to investigate the reversibility of serum Cr levels in patients who took fenofibrate for 5 years. This study showed that 51 days after fenofibrate administration was stopped, there were no differences between the serum Cr levels and eGFR of patients who received fenofibrate and the CG (P=0.3 and P=0.4, respectively). In South Korea, a retrospective study was performed for 36 patients with hypertension who took fenofibrate for 1-3 years.
3) The serum Cr levels of the FG increased by 17.8%±14.0%
(P<0.001), whereas the CG showed no significant changes (P=0.79).
This study differed from the present study in that all the subjects had hypertension.
Furthermore, the present study is distinct from previous studies because the subjects were patients who had visited the clinical examination room; this was not a clinical research study. In addition, we selected patients who did not have cardiovascular disease; the subjects were taking medication for the primary prevention of cardiovascular disease and these patients are usually seen in the primary care setting.
Even though this was a retrospective study, we used PSM to identify groups that were adjusted for age, chronic diseases, and lifestyle, in order to reduce the limitations usually associated with retrospective observational studies.
However, one limitation of the present study is that it would be challenging to generalize the results because the subjects were outpatients at the family medicine department of the only one hospital in Gunposi. However, this facility is not expected to differ significantly from a primary care setting because most patients were there for primary preventive treatment. In this study, we investigated the period 1-12 months after fenofibrate initiation. A previous study showed decreased renal function after taking fibrates for only 1 week, which was still maintained 1 year after the medication was started. 28 
